Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.

10 Apr 2013

New study shows some women don't stick to recommended treatment for breast cancer

One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.

10 Apr 2013

American Cancer Society announces new research, training grants for fiscal year 2013

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013.

9 Apr 2013

Discovery of new signalling pathway creates hope for hormone therapy resistance

A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant.

2 Apr 2013

Copper depletion may prevent breast cancer recurrence

Early trial findings suggest that copper depletion may promote tumor dormancy in patients at high risk for recurrent breast cancer.

18 Feb 2013

University of Utah geneticists engineer mice that develop clear cell sarcoma

Geneticists led by University of Utah Nobel Prize Laureate Mario R. Capecchi, Ph.D., have engineered mice that develop clear cell sarcoma (CCS), a significant step in better understanding how this rare and deadly soft tissue cancer arises. The mouse model also can potentially speed the development of drugs to target genes that must be activated for the cancer to form.

13 Feb 2013

University of Leicester's GENIE to host Lifestyle and Cancer Awareness Workshop on Feb. 23

Women with a family history of breast or ovarian cancer are invited to meet with experts who will advise on preventing or delaying the disease. The University of Leicester's Genetics Education Networking for Innovation and Excellence (GENIE) will hold its third Lifestyle and Cancer Awareness Workshop on Saturday, February 23.

1 Feb 2013

Tamoxifen can counteract some pathologic features in mouse model of DMD

A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death.

16 Jan 2013

Kingston University professor receives prestigious prize for work on drug metabolism

The Dean of the Faculty of Science, Engineering and Computing at London's Kingston University has received a prestigious prize recognising her lifetime's work on drug metabolism.

9 Jan 2013

Manipulating transcription factor can change subtype of breast cancer

Australian scientists have shown how a 'transcription factor' causes breast cancer to develop an aggressive subtype that lacks sensitivity to oestrogen and does not respond to anti-oestrogen therapies such as Tamoxifen and aromatase inhibitors.

28 Dec 2012

Genetic differences in enzyme CYP2D6 play a key role in effectiveness of tamoxifen for breast cancer

For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug's effectiveness and the likelihood breast cancer will recur.

27 Dec 2012

Two hematology/oncology pharmacists to receive 2012 HOPA Foundation Research Award

The HOPA Foundation Board of Directors is pleased to announce the recipients of the 2012 HOPA Foundation Research Award, Dr. Kamakshi Rao for her project Improving & Defining the Impact & Value of Pharmacists in Stem Cell Transplant, and to Dr. Quan Li, for his project, In Vitro Stability of Erlotinib, Lapatinib and Imatinib in Common Compounding Vehicles.

15 Dec 2012

Delayed childbearing may protect against triple-negative breast cancer

Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.

12 Dec 2012

ATLAS holds up 10-year tamoxifen regime

Results from the ATLAS study indicate that women with estrogen receptor-positive breast cancer should consider taking tamoxifen for up to 10 years after diagnosis.

10 Dec 2012

Study finds longer course of tamoxifen treatment cuts breast cancer deaths

The finding that women should be taking the drug for twice as long as is now customary came out of study of nearly 7,000 women from 36 countries.

7 Dec 2012

First Edition: December 6, 2012

Today's headlines include a report that some in the GOP are urging lawmakers to support the idea of trading tax breaks for changes in safety-net programs.

6 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Researchers investigate GPER receptor as possible new drug target for breast cancer

Five-year breast cancer survival rates have improved dramatically over the past 50 years, but tumors can recur up to ten or more years after they are detected. When tumors recur, they are even more difficult to treat.

5 Dec 2012

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

30 Nov 2012

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.

3 Nov 2012